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Ge
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suBACKGROUND The multifactorial pathogenesis leading to dilated cardiomyopathy (DCM) makes stratiﬁcation difﬁcult.
The recent MOGE(S) (morphofunctional, organ involvement, genetic or familial, etiology, stage) classiﬁcation addresses
this issue.
OBJECTIVES The purpose of this study was to investigate the applicability and prognostic relevance of the MOGE(S)
classiﬁcation in patients with DCM.
METHODS This study used patients from the Maastricht Cardiomyopathy Registry in the Netherlands and excluded
patients with ischemic, valvular, hypertensive, and congenital heart disease. All other patients underwent a complete
diagnostic work-up, including genetic evaluation and endomyocardial biopsy.
RESULTS A total of 213 consecutive patients with DCM were included: organ involvement was demonstrated in
35 (16%) and genetic or familial DCM in 70 (33%) patients, including 16 (8%) patients with a pathogenic mutation.
At least 1 cause was found in 155 (73%) patients, of whom 48 (23%) had more than 1 possible cause. Left ventricular
reverse remodeling was more common in patients with nongenetic or nonfamilial DCM than in patients with genetic or
familial DCM (40% vs. 25%; p ¼ 0.04). After a median follow-up of 47 months, organ involvement and higher New York
Heart Association functional class were associated with adverse outcome (p < 0.001 and p ¼ 0.02, respectively). Genetic
or familial DCM per se was of no prognostic signiﬁcance, but when it was accompanied by additional etiologic-
environmental factors such as signiﬁcant viral load, immune-mediated factors, rhythm disturbances, or toxic triggers,
a worse outcome was revealed (p ¼ 0.03). A higher presence of MOGE(S) attributes ($2 vs. #1 attributes) showed an
adverse outcome (p ¼ 0.007).
CONCLUSIONS The MOGE(S) classiﬁcation in DCM is applicable, and each attribute or the gene-environment
interaction is associated with outcome. Importantly, the presence of multiple attributes was a strong predictor of
adverse outcome. Finally, adaptation of the MOGE(S) involving multiple possible etiologies is recommended.
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ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
DCM = dilated cardiomyopathy
EMB = endomyocardial biopsy
HF = heart failure
HTx = heart transplantation
LV = left ventricular
LVEDDI = indexed left
ventricular end-diastolic
diameter
LVEF = left ventricular ejection
fraction
LVRR = left ventricular reverse
remodeling
MOGE(S) = morphofunctional,
organ involvement, genetic or
familial, etiology, stage
NYHA = New York Heart
Association
PCR = polymerase chain
reaction
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1314C lassiﬁcation of cardiomyopathieshas been subject to revisions formore than 60 years (1). To date,
classiﬁcation remains difﬁcult because of
incomplete knowledge about the mecha-
nisms of the disease, its heterogeneous clin-
ical presentation, and overlapping clinical
and molecular ﬁndings (1,2). Dilated cardio-
myopathy (DCM) is a myocardial disease
characterized by left ventricular (LV) dilation
and systolic dysfunction (2). DCM is assumedSEE PAGE 1324
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genesis with common terminal pathophysi-
ology. After exclusion of prevalent causes
(e.g., coronary artery disease [CAD], valvular
disease, congenital disease, hypertension)
(2), DCM comprises poorly deﬁned sub-
groups of cardiac inﬂammation with or
without an infectious agent (3), cytotoxic
medication or drugs (4,5), rhythm distur-bances (6,7), and genetic mutations (8). Nevertheless,
only some persons who are exposed to these triggers
develop DCM. Additionally, in up to 50% of patients,
the cause of DCM remains unknown (4,5).
The hypothesis is that gene-environment inter-
actions (i.e., exposure to an environmental trigger in
addition to an “underlying genetic background”)
may lead to DCM, but a family history of DCM is
present in only 20% to 35% of patients with pre-
dominantly autosomal dominant inheritance (1,8).
The genetic knowledge of cardiomyopathies has
evolved exponentially (1,8), and in view of these
developments, the World Heart Federation published
a new classiﬁcation scheme for cardiomyopathies,
called MOGE(S) (morphofunctional, organ involve-
ment, genetic or familial, etiology, stage) (1). In the
MOGE(S) classiﬁcation, a combination of phenotype,
genetic variation, and etiologic annotation has been
proposed, but studies investigating the applicability
and prognostic value of this new classiﬁcation are
lacking. The routine use of endomyocardial biopsy
(EMB), the referral of all patients with DCM to
our specialized cardiogenetics unit, and long-termd De
he E
, and
repo
Vale
, 201follow-up allowed us to evaluate gene-environment
interactions in a large, well-characterized population
with DCM.
METHODS
STUDY DESIGN. Between 2004 and 2014, 394
consecutive patients with unexplained heart failure
(HF) caused by DCM were enrolled in the Maastricht
Cardiomyopathy Registry. A complete diagnostic
work-up was performed in 213 index patients by using
medical history, 12-lead electrocardiogram, echocar-
diography, Holter monitoring, EMB, and genetic
evaluation (Online Figure 1). Excluded patients with
DCM (n¼ 181) had incomplete diagnostic work-ups and
did not demonstrate signiﬁcant differences in baseline
characteristics (Online Table 1, Online Figure 2). The
protocol was approved by the local ethics committee.
All patients gave written informed consent.
Inclusion criteria were as follows: 1) left ventric-
ular ejection fraction (LVEF) <50% and indexed
left ventricular end-diastolic diameter (LVEDDI) >33
mm/m2 (men) or >32 mm/m2 (women) (9); 2) EMB
performed; 3) genetic evaluation, including coun-
seling, pedigree analysis, and genetic testing in
index patients; and 4) age $18 years.
Exclusion criteria included the following: the
presence of a previous history of myocardial infarc-
tion or signiﬁcant CAD (stenosis >50%) determined
by coronary angiography; primary valvular disease
(mitral regurgitation grade $3, aortic regurgitation
grade $2, or aortic stenosis <1 cm2); hypertensive
heart disease; congenital heart disease; (suspected)
acute myocarditis; and (likely) diagnosis of arrhyth-
mogenic right ventricular dysplasia.
Echocardiographic measurements were performed
in the standard parasternal, apical, and subxiphoid
views (10). Left ventricular reverse remodeling
(LVRR) was deﬁned as an absolute increase in LVEF
of $10% or an LVEF $50% in addition to a decrease in
LVEDDI of $10% or an LVEDDI #33 mm/m2 (11).
Six EMB samples were taken from the right
ventricle. Two to 3 specimens were used for immu-
nohistological analysis and 3 for the detection of viral
genomes by using polymerase chain reaction (PCR)velopment, and the Royal Netherlands Academy of
uropean Commission’s Seventh Framework program
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1315and reverse transcriptase PCR analysis (12). Six
primer pairs were used to detect cardiotropic deox-
yribonucleic acid (DNA) and ribonucleic acid (RNA)
viruses, including adenovirus, enterovirus, cyto-
megalovirus, parvovirus B19, human herpes virus-6,
and Epstein-Barr virus. Signiﬁcant viral load
was deﬁned as $500 copies/mg DNA. Increased car-
diac inﬂammation was deﬁned as $14 inﬁltrating
cells/mm2 (2).
MOGE(S) CLASSIFICATION. All patients had, by
deﬁnition, a morphofunctional diagnosis of DCM.
Extracardiac organ involvement was considered pos-
itive if a specialist proved that the manifestation had
a known or suspected relationship with DCM. Data
considering extracardiac organ involvement were
collected from patients’ records and a standardized
questionnaire, reviewed by 2 investigators. Dis-
agreements were settled by consensus. Extracardiac
organ involvement secondary to HF therapy was not
included.
A minimum of 3 generations of family history of
cardiomyopathy or sudden cardiac death was docu-
mented. Electrocardiography and echocardiography
were performed in all ﬁrst-degree relatives of patients
who consented. Familial inheritance was based on
the presence of 2 or more affected individuals in a
single family or a ﬁrst-degree relative with well-
documented unexplained sudden cardiac death (13)
at age <60 years. Genes were analyzed using Sanger
sequencing (data not included). The selection of
tested genes was based on the expertise of the clinical
geneticist. In speciﬁc cases, noncardiac features or
mixed phenotypes were initially considered based on
clinical assessment, thus leading to evaluation
of additional genes. Variants were classiﬁed in 5
different classes: pathogenic, likely pathogenic,
variant of clinical unknown signiﬁcance, likely
benign, or benign. Pathogenic and likely pathogenic
mutations were classiﬁed as pathogenic mutations,
and others were classiﬁed as nonpathogenic. Genetic
or familial DCM was classiﬁed as the presence of
a familial inheritance pattern or the presence of
a pathogenic mutation, or both.
DCM was divided into 7 causes, in line with the
MOGE(S) classiﬁcation and previous DCM recom-
mendations (1,2,14): 1) genetic or familial; 2) virus-
positive inﬂammatory (Virþ Inﬂþ); 3) virus-positive
inﬂammatory-negative (Virþ Inﬂ); 4) virus-
negative inﬂammatory (Vir Inﬂþ); 5) virus-negative
inﬂammatory negative with proven systemic disease
(Vir Inﬂ systemicþ); 6) rhythmogenic (tachycar-
diomyopathy not improving, >20% premature ven-
tricular beats) (6,7); and 7) toxic (alcohol abuse, hard
drugs, chemotherapy) (4,5). Stage of HF was classiﬁedaccording to the New York Heart Association (NYHA)
functional classiﬁcation.
FOLLOW-UP. Patients were followed for at least
12 months after EMB, except for 1 patient, who died
after 2 months. Follow-up data on death, heart
transplantation (HTx), and life-threatening ventricu-
lar arrhythmias were collected using medical records,
municipal population register, or telephone contact
with general practitioners. End of follow-up was
January 1, 2014. No patient was lost to follow-up.
Echocardiography after 12 months (range, 6 to
18 months) was available in 93% of patients. The
primary endpoint was the combination of HTx-free
survival without life-threatening ventricular arrhy-
thmias. Life-threatening ventricular arrhythmias
were deﬁned as nonfatal ventricular ﬁbrillation (with
or without implantable cardioverter-deﬁbrillator
shock), hemodynamic unstable ventricular tachy-
cardia, or sustained ventricular tachycardia with
implantable cardioverter-deﬁbrillator shock.
The Online Appendix contains a more detailed
description of the study methods.
STATISTICAL ANALYSIS. Variables are displayed as
numbers (percentage), mean  SD, or median (inter-
quartile range), as appropriate. Categorical variables
were compared using chi-square test or Fisher exact
test. Continuous variables were compared using
Student t test or Mann-Whitney U test. The Kaplan-
Meier method was used to calculate survival curves
(comparison between groups by log-rank test). Uni-
variable Cox proportional hazards regression analysis
was performed to assess clinical and demographic
covariates associated with event-free survival. We
tested for interactions between all covariates used in
the univariable analysis. Etiology was consistently
modeled as the presence or absence of 1 or more
nongenetic causes unless indicated otherwise. Sta-
tistical signiﬁcance was accepted at p < 0.05.
Statistical analysis was performed using SPSS version
21.0 (IBM Corporation, Armonk, New York) software.
RESULTS
Baseline characteristics are summarized in Table 1.
More than one-half of the patients were male.
Genetic or familial DCM was diagnosed in approxi-
mately one-third of patients. The cardiac presence of
2 viruses was seen in 47 (23%) patients. Two patients
had triple viral presence: parvovirus B19, human
herpes virus-6, and Epstein-Barr virus. Viral presence
was demonstrated in 47 (79%) patients with earlier
viral prodromes. A signiﬁcant viral load was demon-
strated in only 36 (18%) patients, predominantly
revealing parvovirus 19 infection. Dual infections
TABLE 1 Baseline Patient Characteristics
All
(N ¼ 213)
Genetic or
Familial DCM
(n ¼ 70)
Nongenetic or
Familial DCM
(n ¼ 143) p Value
Age at onset, yrs 51  13 50  13 51  12 0.65
Sex, male/female 128/85 41/29 87/56 0.75
Heart rate, beats/min 74  15 73  16 75  15 0.45
SBP, mm Hg 129  20 126  20 130  20 0.22
DBP, mm Hg 79  12 78  10 79  13 0.58
Body height, cm 175  9.6 174  9.7 175  10 0.51
Body weight, kg 82  18 80  18 83  18 0.33
BSA, m2 1.6  0.27 1.5  0.27 1.6  0.27 0.32
Symptoms
Fatigue 75 (35) 25 (36) 50 (35) 0.91
Angina 35 (16) 13 (19) 22 (15) 0.56
Dyspnea 146 (69) 41 (59) 105 (73) 0.03
Peripheral edema 26 (12) 7 (10) 19 (13) 0.49
Palpitation 43 (20) 14 (20) 29 (20) 0.96
Dizziness 14 (7) 7 (10) 7 (5) 0.16
Syncope 9 (4) 5 (7) 4 (3) 0.14
Viral prodromes 64 (30) 18 (26) 46 (32) 0.47
OHCA 21 (10) 6 (9) 15 (10) 0.66
NYHA functional class
I 62 (29) 29 (41) 33 (23) 0.006
II 73 (34) 21 (30) 52 (36) 0.36
III 46 (22) 10 (14) 36 (25) 0.07
IV 32 (15) 10 (14) 22 (15) 0.83
$III 78 (37) 20 (29) 58 (41) 0.09
Symptom duration, months 9 (3-30) 9 (2-35) 9 (4-26) 0.84
Genetic/familial DCM 70 (33) 70 (100) 0 (0)
Inheritance pattern þ
Autosomal dominant 64 (30) 64 (91) 0 (0) <0.001
X-linked recessive 1 (1) 1 (1) 0 (0) <0.001
Pathogenic mutation 11 (5) 11 (16) 0 (0) <0.001
Inheritance pattern
Pathogenic mutation 5 (2) 5 (7) 0 (0) <0.001
ECG
LBBB 55 (26) 18 (26) 37 (26) 0.98
AV block 10 (5) 7 (10) 3 (2) 0.02
Atrial ﬁbrillation 35 (17) 14 (20) 21 (15) 0.40
Continued on the next page
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with genetic or familial DCM had similar viral pres-
ence or signiﬁcant viral load, as compared with pa-
tients with nongenetic or nonfamilial DCM (81% vs.
79%; p ¼ 0.74 and 21% vs. 15%; p ¼ 0.25, respectively).
MOGE(S) CLASSIFICATION. According to the MOGE(S)
classiﬁcation (Table 2), skeletal muscle involvement
showed the highest prevalence (5%), followed by
ocular involvement, including episcleritis (n ¼ 3),
uveitis anterior (n ¼ 2), and uveitis posterior (n ¼ 2).
Cutaneous involvement was seen in 3%, including
vascular purpura (n ¼ 5) and alopecia (n ¼ 2). We
identiﬁed 2 patients with gene mutations associated
with extracardiac organ involvement: 1 patient
with autosomal dominant Emery-Dreifuss musculardystrophy (LMNA mutation) and the other with pre-
viously unrecognized Becker dystrophy (DMD muta-
tion) with a mild phenotype.
A total of 18 pathogenic mutations in 16 (8%)
patients were found (Online Figure 3, Online Table 2).
A signiﬁcant lower yield of pathogenic mutations was
demonstrated in patients with nonfamilial DCM as
compared with patients with familial DCM (4% vs.
17%; p < 0.001).
Multiple possible causes were found in 48 (23%)
patients, with the most prevalent combination of
genetic predisposition and increased cardiac inﬂam-
mation or viral infection in 15 (7%) and 9 (4%) pa-
tients, respectively. Three causes were demonstrated
in 7 (3%) patients with the most prevalent com-
bination of genetic or familial, Vir Inﬂþ, DCM, and
rhythm in 4 (2%) patients. One patient demonstrated
4 causes, including increased cardiac inﬂammation
without virus, genetic or familial, rhythm, and toxic
exposure. Examples of patients using MOGE(S)
annotations are given in Table 3.
SHORT-TERM AND LONG-TERM FOLLOW-UP WITH
PREDICTION OF OUTCOME. Echocardiographic mea-
surements after a mean of 1 year demonstrated LVRR
in 70 (35%) patients (Table 2, Online Table 3).
A signiﬁcantly lower rate of LVRR was present in
patients with genetic or familial compared with
nongenetic or nonfamilial DCM (25% vs. 40%;
p ¼ 0.04). In contrast, the rate of LVRR was signiﬁ-
cantly higher in patients with toxic DCM versus not
toxic DCM (75% vs. 33%; p ¼ 0.003). The 3 toxic-
triggered patients without LVRR after 12 months
were persons who continued abusing alcohol.
Whether patients had 1 cause or multiple possible
causes, no signiﬁcant differences in LVRR were seen
after 12 months.
During a median follow-up of 47 months (inter-
quartile range, 30 to 67 months), 26 (13%) patients
reached the primary endpoints of death (n ¼ 15;
annual mortality 1.6%), HTx (n ¼ 1), or life-
threatening arrhythmias (n ¼ 12). Regarding the
MOGE(S) classiﬁcation, the presence of extracardiac
organ involvement or NYHA functional class $III
showed a signiﬁcantly worse outcome compared
with those patients without extracardiac organ
involvement or NYHA functional class <III (Table 4,
Central Illustration) (p < 0.001 and p ¼ 0.02, respec-
tively). The incidence of the primary endpoint was
similar in genetic or familial DCM and in nongenetic
or nonfamilial DCM (Table 4, Central Illustration)
(p ¼ 0.36). Additionally, there was no difference
in outcome between patients with 1 or more nonge-
netic, environmental causes (signiﬁcant viral load,
immune-mediated condition, rhythm disturbances,
TABLE 1 Continued
All
(N ¼ 213)
Genetic or
Familial DCM
(n ¼ 70)
Nongenetic or
Familial DCM
(n ¼ 143) p Value
Echocardiography
LVEF, % 29  11 31  10 29  11 0.72
LVEDD, mm 62  8 61  7 62  9 0.81
LVEDDI, mm/m2 40  8 40  7 41  8 0.31
Comorbidities
History of hypertension 83 (39) 25 (36) 58 (41) 0.50
Hyperlipidemia 36 (17) 13 (19) 23 (16) 0.60
OSAS 21 (10) 9 (13) 12 (8) 0.30
Diabetes mellitus 23 (11) 5 (7) 18 (13) 0.21
Hyperthyroidism 3 (1) 2 (3) 1 (1) 1.00
Hypothyroidism 6 (3) 2 (3) 4 (3) 1.00
Systemic disease* 17 (8) 1 (1) 16 (11) 0.01
EMB
Cardiac inﬂammation 87 (41) 27 (39) 60 (42) 0.70
CD3þ, cells/mm2 4.7 (2–8) 3.7 (2–8) 5.2 (3–9) 0.05
CD45þ, cells/mm2 8.5 (6–13) 8.0 (5–13) 9 (6–14) 0.26
CD68þ, cells/mm2 3.0 (1–6) 2.6 (1–5) 3.3 (1–7) 0.50
Fibrosis, % 5.7 (3–10) 5.5 (2–12) 6.0 (3–10) 0.51
Viral presence 162 (76) 52 (74) 110 (77) 0.73
Parvovirus B19 152 (71) 48 (69) 104 (73) 0.99
HHV6 48 (23) 22 (31) 26 (18) 0.02
Epstein-Barr virus 11 (5) 2 (3) 9 (6) 0.29
Adenovirus 4 (2) 0 (0) 4 (3) 0.31
Enterovirus 0 (0) 0 (0) 0 (0) -
Medication
Beta-blocker 197 (92) 66 (94) 131 (92) 0.41
% opt 50 (25–75) 50 (25–56) 50 (25–75) 0.79
ACE inhibitor or ARB 203 (95) 64 (91) 139 (97) 0.08
% opt 50 (25–63) 50 (25–100) 50 (25–50) 0.10
MRA 69 (32) 18 (26) 51 (36) 0.15
Diuretics 131 (62) 43 (61) 88 (62) 0.90
Digoxin 29 (14) 10 (14) 19 (13) 0.85
Devices
ICD 102 (48) 35 (50) 67 (47) 0.66
CRT 41 (19) 13 (19) 28 (20) 0.83
Pacemaker 5 (2) 1 (1) 4 (3) 1.00
Values are mean  SD, n, n (%), or median (interquartile range). *Discovered after diagnosis of DCM.
% opt ¼ percentage of optimal doses; ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor
blocker; AV ¼ atrioventricular; BSA ¼ body surface area; CRT ¼ cardiac resynchronization therapy; DBP ¼
diastolic blood pressure; DCM ¼ dilated cardiomyopathy; ECG ¼ electrocardiogram; EMB ¼ endomyocardial
biopsy; HHV6 ¼ human herpes virus-6; ICD ¼ implantable cardioverter-deﬁbrillator; LBBB ¼ left bundle branch
block; LVEDD ¼ left ventricular end-diastolic diameter; LVEDDI ¼ indexed LVEDD; LVEF ¼ left ventricular
ejection fraction; MRA ¼ mineralocorticoid receptor antagonist; NYHA ¼ New York Heart Association; OHCA ¼
out-of-hospital cardiac arrest; OSAS ¼ obstructive sleep apnea syndrome; SBP ¼ systolic blood pressure.
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1317or toxic triggers) versus those without an identiﬁable
nongenetic, environmental cause (Table 4, Central
Illustration) (p ¼ 0.54). Moreover, no cumulative
detrimental effect of the number of either nongenetic
causes or all possible causes on outcome was found
(p ¼ 0.28 and p ¼ 0.29, respectively; data not shown).
In addition to the MOGE(S) attributes, a lower LVEF
was also associated with worse outcome (Table 4).
After testing for interactions among all covariates,
only genetic or familial and nongenetic, envir-
onmental causes showed a signiﬁcant interaction
(p ¼ 0.03). Interestingly, a worse outcome was
demonstrated in patients with genetic or familial
DCM combined with at least 1 additional nongenetic,
environmental factor compared with patients with
only a genetic predisposition (Figure 1A) (p < 0.05).
Similar results were found comparing this gene-
environment interaction group with all other pa-
tients without these combined triggers (Figure 1B)
(p ¼ 0.03). Excluding patients with proven systemic
disease in the last 2 analyses demonstrated similar
results (p < 0.05 and p ¼ 0.02, respectively; data not
shown).
Using a scoring system assigning 1 point to
each attribute or the gene-environment interaction
(organ involvement [O], gene-environmental etiology
[G þ E], and NYHA functional class [S]), signiﬁcant
worse outcome was evident in patients with MOGE(S)
$2 points versus MOGE(S) #1 (Figure 1C) (p < 0.007).
DISCUSSION
The newly proposed MOGE(S) classiﬁcation is appli-
cable, with prognostic value in patients diagnosed
with DCM (Central Illustration). All tested attributes of
the MOGE(S) classiﬁcation proved to be associated
with worse outcome. Nonetheless, prognosis overall
was favorable in this cohort of patients with well-
deﬁned DCM, independent of prognostic risk fac-
tors. Furthermore, our results demonstrate that a
cause can be found in more than 70% of patients with
DCM, and more than 1 possible cause is present in
approximately one-fourth of patients.
MULTIFACTORIAL PATHOGENESIS OF DCM. During
the past decade, several environmental causes of
DCM development have been discovered. In parallel,
more than 40 genes causing DCM have been identi-
ﬁed, many of which are also associated with pheno-
types besides DCM. This situation illustrates the
complexity of this multifactorial disease and has led
to continuous revision of the classiﬁcation system
proposed by the American Heart Association (9),
the European Society of Cardiology (15), and the
World Health Organization (16). In view of the last-mentioned system, the World Heart Federation pro-
posed a new classiﬁcation system for myocardial
disorders that is called MOGE(S) (1). This system ex-
tends previous classiﬁcations by including the extent
of organ involvement and the severity of HF.
Although only 1 etiologic annotation is applicable
in the current MOGE(S) classiﬁcation system, our re-
sults indicate that more than 1 possible cause can be
found in one-fourth of patients DCM who undergo
TABLE 3 Examples of MOGE(S) Annotations in Patients With DCM
Example MOGE(S)
Genetic mutation MD OHþM GAD EG-LMNA[p.Lys270Lys, predicting aberrant splicing] SNYHA-2
Multiple genetic mutations MD OH GAD EG-MYBPC3[p.Arg1022Pro] þ PLN[p.Arg14Del] SNYHA-4
Genetic mutation and viral
myocarditis
MD OHþM GXLR EG-DMD[Del exons 45-48] þ M:PVB19 (1147 copies/mcg DNA)
SNYHA-3
Immune-related conditions MD OHþLUþE GN EAI-P [sarcoidosis] SNYHA-2
Toxic exposure MD OH GN ET [anthracyclines] SNYHA-2
Rhythm disturbances MD OH GN ER [34% PVC] SNYHA-3
M ¼morphofunctional: D ¼ dilated cardiomyopathy; O¼ organ involvement: H ¼ heart, M ¼muscle-skeletal, LU¼
lungs, E ¼ eye; G¼ genetic or familial: AD ¼ autosomal dominant, XLR ¼ X-linked recessive, N ¼ negative;
E¼ etiology: G ¼ genetic followed by speciﬁc mutation(s), M ¼ myocarditis followed by speciﬁc cause, PVB19 ¼
parvovirus B19, mcg ¼ micrograms, AI-P ¼ proven auto-immune disease followed by speciﬁc disease, T ¼ toxic
followed by speciﬁc exposure, R ¼ rhythm disturbances followed by speciﬁc arrhythmia, PVC ¼ premature ven-
tricular complex, 34% PVC ¼ 34% premature ventricular complexes of total QRS complexes; S ¼ stage of disease:
NYHA ¼ New York Heart Association.
TABLE 4 Association of Variables With Combined Endpoint*
Univariable Analysis
p ValueHR 95% CI Wald Test
Demographics
Age, per 1 yr 1.01 0.98–1.05 0.39 0.53
Male 0.74 0.33–1.66 0.53 0.46
Medical history
Duration of symptoms,
per 1 yr
0.90 0.75–1.06 1.55 0.21
History of hypertension 0.41 0.15–1.09 3.20 0.059
Atrial ﬁbrillation 1.54 0.64–6.78 1.84 0.31
Complete LBBB 1.07 0.45–2.54 0.02 0.89
Hyperlipidemia 0.22 0.03–1.63 2.19 0.14
Diabetes mellitus 0.04 0.00–7.20 1.47 0.23
OSAS 1.77 0.61–5.16 1.11 0.29
Hyperthyroidism 2.30 0.31–17.0 0.66 0.42
Hyperthyroidism 2.75 0.65–12.0 1.88 0.17
Systemic disease 0.94 0.22–3.97 0.007 0.93
Echocardiography
LVEF, per 1-U 0.96 0.93–1.00 4.08 0.043†
LVEDD, per 1-U 1.04 1.00–1.08 2.74 0.098
MOGE(S)
(O)rgan involvement 3.34 1.50–7.45 8.68 0.003†
(G)enetic or familial
inheritance
1.43 0.66–3.09 0.82 0.37‡
(E)tiology known 0.75 0.34–1.64 0.53 0.47‡
Number of nongenetic
etiologies
1.17 0.74–1.85 0.44 0.51
(G)þ(E) 2.38 1.06–5.35 4.41 0.036†‡
(S)tage of disease:
NYHA$3
2.43 1.13–5.23 5.12 0.024†
*Death, heart transplantation, life-threatening arrhythmia. †Variables were
considered signiﬁcant at the 95% conﬁdence interval (p < 0.05). ‡Signiﬁcant
interaction between covariates (p < 0.05).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
TABLE 2 MOGE(S) Classiﬁcation*
Attribute Present
(Rate of LVRR)
Attribute Not Present
(Rate of LVRR) p Value
(M)orphofunctional
DCM 35 (70/198) — —
(O)rgan involvement 30 (9/30) 36 (61/168) 0.38
Skeletal muscle 29 (2/7) 36 (68/191) 0.70
Auditory system 60 (3/5) 35 (67/193) 0.35
Kidney 25 (1/4) 36 (69/194) 1.00
Nervous system 50 (1/2) 35 (69/196) 1.00
Liver 0 (0/2) 36 (70/196) 0.54
Gastrointestinal system 50 (1/2) 35 (69/196) 0.54
Cutaneous 40 (2/5) 35 (68/193) 1.00
Ocular system 40 (2/5) 35 (68/193) 1.00
Mental retardation 0 (0/1) 36 (70/197) 1.00
(G)enetic or familial 25 (15/61) 40 (55/137) 0.04
pathogenic mutation 13 (2/16) 37 (68/182) 0.05
(E)tiology (nongenetic) 36 (43/120) 35 (27/78) 0.86
Idiopathic 41 (22/54) 33 (48/144) 0.33
Viral infection 38 (14/37) 35 (56/161) 0.73
Virþ Inﬂ 35 (8/23) 35 (62/175) 0.95
Virþ Inﬂþ 43 (6/14) 35 (64/184) 0.57
Immune-mediated 35 (27/78) 36 (43/120) 0.86
Vir Inﬂþ 38 (26/69) 34 (44/129) 0.62
Vir Inﬂ Systþ 11 (1/9) 37 (69/189) 0.16
Rhythm disturbances 24 (4/17) 37 (66/181) 0.43
Toxic exposure 75 (9/12) 33 (61/186) 0.003
(S)tage of heart failure
NYHA functional class $III 42 (31/74) 32 (39/124) 0.14
Number of possible etiologies† 0.70‡
0 41 (22/54) 35 (68/190) 0.72
1 33 (30/92)
2 39 (17/44)
$3 25 (2/8)
Values are % (n/N). *Patients (n ¼ 198) with echocardiographic follow-up showing the rates
of LVRR after 12 months as a function of each attribute. †Includes genetic and nongenetic
etiologies. ‡Overall p value.
LVRR ¼ left ventricular reverse remodeling; Virþ Inﬂ ¼ virus-positive inﬂammatory-negative
DCM; Vir Inﬂþ ¼ virus-negative inﬂammatory DCM; Virþ Inﬂþ ¼ virus-positive inﬂammatory
DCM; Vir Inﬂ Systþ ¼ virus-negative, inﬂammatory-negative DCM with proven systemic
disease; other abbreviations as in Table 1.
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1318a comprehensive diagnostic work-up. Importantly,
the combination of multiple causes (genetic predis-
position combined with an additional etiologic-
environmental factor) revealed signiﬁcant prognostic
relevance. This ﬁnding is in line with current
consensus that DCM is an end stage of a multifactorial
pathogenesis leading to a single, ﬁnal phenotype
(8,17). In view of this, adaptation of the etiologic
annotation in the MOGE(S) classiﬁcation system is
required. Moreover, excluding patients with DCMwho
also have CAD or hypertension, all possible evolving
comorbidities during a patient’s aging process, re-
mains a limitation of all DCM classiﬁcation systems. As
for any other disease, comorbidities can be present,
but they may not have a clinical inﬂuence on the DCM
phenotype. In the future, the concept of excluding
common causes of DCM (e.g., hypertension or CAD)
may change with expanding knowledge of disease
modiﬁers.
Finally, our results demonstrate that after a
comprehensive diagnostic work-up, including genetic
CENTRAL ILLUSTRATION Event-Free Survival Curves for Patients With DCM for All Different Attributes of the MOGE(S) Classiﬁcation
Hazebroek, M.R. et al. J Am Coll Cardiol. 2015; 66(12):1313–23.
Event-free survival curves of patients with dilated cardiomyopathy (DCM) compare the following: (A) the presence or absence of organ involvement; (B) patients with
genetic or familial versus nongenetic or nonfamilial DCM; (C) patients with DCM versus without a nongenetic, environmental cause (signiﬁcant viral load, increased
cardiac inﬂammation, rhythm disturbances, or toxic triggers); and (D) patients with DCM with New York Heart Association (NYHA) functional class <III versus NYHA$III.
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1319evaluation and EMB, a possible cause for DCM can be
found in 73% of patients. This ﬁnding differs from
previous reports of large populations of patients with
DCM that described a cause of DCM in 50% of patients
(4,5). The most likely explanations for this difference
are the use of immunohistochemistry testing for
detection of (low-grade) cardiac inﬂammation, DNA/
RNA extraction for viral presence detection, and ge-
netic testing, methods that were largely not available
at the time of the previous reports.
Although our clinical genetics department per-
forms routine assessment of organ involvement, withreferral to a designated specialist if needed, it proved
to be difﬁcult in some cases to apply the MOGE(S)
classiﬁcation in this study because organ involve-
ment is not fully speciﬁed in the proposal. We
recognize the importance of extracardiac organ
involvement, which can offer preliminary diagnostic
clues and identify “red ﬂags.” In view of the latter,
several immune-mediated diseases can have distinct
extracardiac involvement (e.g., sarcoidosis), although
other disorders may have indistinct involvement. For
instance, in patients with increased cardiac inﬂam-
mation without an identiﬁable cause, classifying
FIGURE 1 Event-Free Survival Curves for DCM Subgroups
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Event-free survival curves demonstrate the cumulative impact of genetic and other factors on patients with dilated cardiomyopathy (DCM). Subgroups
compared included (A) patients with familial or genetic DCM and at least 1 additional etiologic-environmental factor (signiﬁcant viral load, immune-
mediated condition, rhythm disturbances, or toxic triggers: Gen1þ add. etiology$1) versus patients with DCM who had only familial or genetic DCM
(Gen1þ no add. etiology0); (B) patients with familial or genetic DCM and at least 1 additional etiologic-environmental factor versus all patients with DCM
without this combination (only familial or genetic, only nongenetic cause, or neither); and (C) patients with DCM with $2 positive MOGE(S) attributes versus
those with #1 positive attribute.
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1320extracardiac involvement remains difﬁcult when as-
sociations are unknown. Therefore, extracardiac
organ involvement was considered positive only if
the condition was proved by a specialist and had a
known or suspected relationship with the cause of
DCM. Interestingly, organ involvement was a strong
independent predictor of outcome. This association
may reﬂect disease severity, in which extracardiac
organ involvement may represent an advanced stage
of the underlying systemic or genetic disease. In
contrast, hitherto unknown or unidentiﬁed syn-
dromes may underlie the DCM phenotype in these
patients.
A familial inheritance pattern was found in one-
third of patients, similar to previous reports (18,19).A pathogenic mutation was identiﬁed in 16 (8%) pa-
tients with DCM: 11 had a positive family history, and
5 had phenotypically sporadic DCM. This ﬁnding
extends the current knowledge that genetic testing
should not be restricted to familial cases because
variable expression or incomplete family history may
inﬂuence the inheritance pattern. Moreover, genetic
defects can be de novo, have an age-dependent
penetrance, or be present in unique survivors or
small families, again masking a familial inheritance.
Several relatively large studies have evaluated a
genetic cause for DCM. Hershberger et al. identiﬁed a
putative genetic cause in 20% to 30% of >300 index
patients with DCM (20–23). Two studies using a setup
similar to ours identiﬁed a pathogenic mutation in
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132117% to 20% of their patients with DCM (24,25). How-
ever, 52% to 58% of patients in the latter studies had a
positive family history of DCM versus 31% in our
cohort. Therefore, the higher yields of pathogenic
mutations in the previous studies could be explained
by the following: our routine referral of all patients
with DCM, irrespective of an already known nonge-
netic cause or a positive family history; regional
differences in incidence or prevalence of gene muta-
tions, whereas founder mutations can strongly
determine the yield of pathogenic mutations (25); or
number of genes tested per patient.
Genetics in DCM remains challenging because of
the high number of disease-speciﬁc and candidate
genes and the presence of many rare or novel muta-
tions, usually speciﬁc for a single individual or
family (“private” mutations), as well as difﬁculties in
determining whether DNA variants are clinically
relevant, particular in the era of next-generation
sequencing (8). Thus, irrespective of the number of
genes tested, it is likely that the number of genes
inﬂuencing the phenotype of DCM is signiﬁcantly
higher than currently known. Although more than
40 causative genes for DCM development are
described, few studies exist on genotype-phenotype
correlations and their impact on outcome. Several
mutations are associated with prominent conduction
disease and arrhythmia (DES, LMNA, SCN5A, PLN),
whereas LMNA and PLN carriers in particular have a
high prevalence of both life-threatening ventricular
arrhythmias and end-stage HF (26,27). Although a
recent paper demonstrated a signiﬁcantly worse
outcome in patients with DCM who had a pathogenic
mutation compared with no pathogenic mutation
(25), the result was highly dependent on the high
prevalence of the PLN founder and LMNA mutations
(74% of patients with pathogenic mutations). The
relatively low prevalence of the latter mutations in
our cohort may explain why we did not observe a
worse long-term outcome in patients with familial or
genetic DCM.
Furthermore, the lower rate of LVRR in familial or
genetic DCM may be explained by the predominance
of sarcomeric mutations that inﬂuence cardiac
structure and function without a strong effect on
long-term outcome. In contrast to other nongenetic
environmental factors that may reverse spontane-
ously or after therapy, the genetic or familial cause is
irreversible. Moreover, the fact that we performed
genetic analysis in all consenting patients, indepen-
dent of DCM severity or the presence of a nongenetic
cause, may have led to a broad spectrum of pheno-
typic expression of speciﬁc gene mutations that could
account for a less severe phenotype in our study. It islikely that not all mutations associated with DCM are
equally malignant; that seems to be the case in our
population. Finally, the paradoxical ﬁnding that
familial or genetic DCM negatively predicts LVRR but
not long-term outcome may also reﬂect the fact
that clinical outcome (death, HTx, life-threatening
arrhythmias) and LVRR (morphofunctional improve-
ment) are in part independent of each other and
therefore may be determined by different etiologic
factors.
Routine use of EMB allowed us to evaluate both
viral presence and cardiac inﬂammation and their
relationship with genetic background. Our results
demonstrating viral presence in 76% of patients with
DCM and increased cardiac inﬂammation in 41% of
patients with DCM are in line with previous reports
(28,29). As previously shown, viral infection may
cause cardiac inﬂammation, and viral persistence
may play a contributory role in developing DCM (30).
Although almost 90% of adults will encounter one of
these viruses during their life, as demonstrated by the
presence of serologic anti-immunoglobulin G in a
large population study, few will develop cardiac
sequelae (31). This ﬁnding suggests that viral sus-
ceptibility, possibly genetically predisposed, plays
an important role in the development of DCM, as
reﬂected in our results demonstrating that no single
cause determines outcome, which instead stems from
the combination of genetic predisposition and an
additional etiologic-environmental factor. Therefore,
susceptibility to DCM development should not be
restricted to viruses and cardiac inﬂammation, but to
all triggers that can either cause or contribute to DCM
after excluding other, more prevalent causes.
Implementation of the MOGE(S) classiﬁcation may
play a signiﬁcant role in stratifying patients who will
beneﬁt most from etiologically based treatments, in
addition to a standard HF regimen. However, whether
the latter approach improves outcome in terms of
LVRR or event-free survival remains to be tested
prospectively. Given that the outcome largely
depends on the gene-environment interaction, we
recommend genetic evaluation of all patients with
DCM irrespective of the suspicion of another nonge-
netic cause of the disease and, similarly, would
recommend further etiologic examinations including
consideration of cardiac biopsies in patients with
DCM and a proven gene mutation.
A signiﬁcant percentage of our patients (27%)
received etiologically based treatment strategies,
such as intravenous immunoglobulins or immuno-
suppressive therapy in those patients demonstrating
(viral) inﬂammatory DCM. Although the nonran-
domized nature of this study is unable to prove a
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Each
component of the MOGE(S) classiﬁcation scheme for
patients with DCM is associated with prognosis. The
strongest predictors of adverse outcome are involve-
ment of organs other than the heart, higher New York
Heart Association functional class, and the product of
gene-environment interaction.
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: Genetic evaluation of patients with
DCM may have prognostic implications even when
nongenetic causes are identiﬁed and vice versa.
TRANSLATIONAL OUTLOOK: More research in
larger cohorts of patients with DCM of various causes
(genetic and nongenetic) is needed to identify vari-
ables other than those captured by the MOGE(S)
classiﬁcation that are associated with clinical
outcomes and have therapeutic implications.
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1322beneﬁcial effect of our treatment strategies, we do
show excellent survival rates after a mean of more
than 4 years.
STUDY LIMITATIONS. This study represents an un-
biased analysis of the clinical, biological, and
morphometric data derived from using predeﬁned
deﬁnitions to predict outcome and functional
improvement. Patients with DCM comprise a hetero-
genic patient population, predominantly because of
the still exploratory nature of this ﬁeld, in which
many entities remain unknown. With respect to LVRR
after 12 months, classifying patients into these pre-
deﬁned subgroups sometimes resulted in a relatively
small number of patients. Therefore, these results
should be interpreted with caution. Although we
routinely perform EMB and refer all patients with
DCM for genetic screening, a potential selection bias
may have occurred because not all patients consented
to these investigations. Nevertheless, comparison of
baseline characteristics between selected and ex-
cluded patients did not show any signiﬁcant differ-
ence. Although the most evidence-based or severe
(early-onset, worse prognosis) pathogenic mutations
(MYH7, TPM1, LMNA, DES) were tested in 92% of
patients, the number of index patients screened for
each gene differed as a result of ongoing recruitment
of patients over a period of 10 years and improved
insight into different genes that could cause DCM.
Because of the relative low event rate in our cohort,
the current study had insufﬁcient power to perform
multivariable modeling to test for independent pre-
dictors of outcome.
CONCLUSIONS
Our results revealed that improved stratiﬁcation of
patients with DCM is possible by using the attributes of
the MOGE(S) classiﬁcation by combining genetic
evaluation and nongenetic, environmental factors,
including EMB. The paradoxical ﬁnding that genetic or
familial DCM was a negative predictor of short-termLVRR, whereas only the gene-environment interac-
tion was a negative predictor of long-term outcome,
raises interest. In the future, knowing one’s genetic
predisposition may have clinical implications because
preventive measures would bemore important in such
patients and their relatives. Finally, our study
demonstrated that a complete diagnostic work-up
increased diagnostic yield and is associated with
excellent survival rates, if the underlying cause of
DCM is recognized and treated accordingly.
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